Wedbush Upgrades Harpoon Therapeutics (HARP) to Outperform

Wedbush analyst Robert Driscoll upgraded Harpoon Therapeutics (NASDAQ: HARP) from Neutral to Outperform with a price target of $7.00 (from $5.00).

For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.

Shares of Harpoon Therapeutics closed at $2.00 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
• Tata Motors Passenger Vehicles (TMPV:IN) PT Raised to INR375 at ICICI Securities